Denise Myshko

Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@onclive.com

Articles

Tipifarnib Shows Potential in HRAS-Mutant Head and Neck Cancers

November 4th 2020

Investigators are testing tipifarnib, a novel drug that inhibits a critical enzyme needed for HRAS activation, in patients with head and neck squamous cell carcinoma whose tumors harbor the mutation.

MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases

October 23rd 2020

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential therapies to treat brain metastases and those with cancers refractory to available therapies.

Investigators Tackle New NSCLC Target With Glutaminase Inhibitor

October 19th 2020

Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.

Eprenetapopt May Develop Into New Option for TP53-Mutant MDS

October 7th 2020

The addition of the experimental small molecule eprenetapopt to a standard treatment for myelodysplastic syndromes is showing promise in patients with TP53 mutations.

Pemigatinib Trial Seeks to Build on Targeted Advances in Cholangiocarcinoma

September 22nd 2020

An explosion of research in the field led to the approval of pemigatinib in April 2020 for patients with unresectable, previously treated advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.

Entrectinib Shows Intracranial Response in NTRK+ Tumors and CNS Metastases

September 20th 2020

Entrectinib demonstrated durable intracranial activity in a small subset of patients with NTRK fusion–positive solid tumors and baseline central nervous system metastases.

Futibatinib Demonstrates Promising Responses in FGFR2+ Intrahepatic Cholangiocarcinoma

September 17th 2020

In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, futibatinib was shown to be efficacious and tolerable.

Ofatumumab to Be Available Through a Patient Access Program for CLL

September 10th 2020

Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.

UPMC Trial Explores Optimal Duration of Checkpoint Immunotherapy

September 3rd 2020

Investigators at UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, have launched a clinical trial to determine the impact on patient outcomes of stopping therapy after 1 year.

Osimertinib Results Show Potential for Earlier TKI Use in EGFR-Mutant NSCLC

July 27th 2020

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

COVID-19 Is Expected to Have Long-term Impact on Oncology Practices

June 25th 2020

The rapidly developing nature of our knowledge about the coronavirus disease 2019 and the need to respond quickly to the pandemic are prompting community oncologists to search for ways to maintain their practices while improving the quality of care for their patients.

Enfortumab Vedotin Demonstrates Additional Mechanisms of Action in UC Models

June 23rd 2020

In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.

Subcutaneous Daratumumab Offers Convenience for Patients With Multiple Myeloma

June 21st 2020

Nearly 5 years after its approval for patients with multiple myeloma, daratumumab is now available in a formulation that can be administered in a fraction of the time required with the original agent.

AI Makes Inroads Into Oncology Practice

June 17th 2020

Oncology practices large and small are starting to tap into the power of data analytics and artificial intelligence to help identify patients at risk of relapse or adverse effects and to assist in making clinical decisions on care.

Early Data Show CC-93269 has Activity in Multiple Myeloma

June 13th 2020

Interim results from a phase 1 trial show CC-93269 has activity in highly refractory, heavily pretreated patients with multiple myeloma, with an acceptable safety profile.

Adding Subcutaneous Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis

June 13th 2020

Subcutaneous daratumumab may be a promising treatment for newly diagnosed patients with light chain amyloidosis who are in urgent need of new treatment options.

Omitting Radiation Does Not Reduce Survival for Patients with Early Unfavorable HL

June 12th 2020

Radiation therapy can be omitted in patients with newly diagnosed early-stage unfavorable Hodgkin lymphoma without sacrificing efficacy.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

May 31st 2020

Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC

May 27th 2020

The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).